Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Next Previous
X
Search
Trial Profile

A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics; Registrational
  • Sponsors Corium International

    • Most Recent Events

    • 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
    • 16 Mar 2022 According to a KemPharm media release, ADLARITY has been approved (donepezil transdermal system) by the U.S. Food and Drug Administration (FDA) on March 11, 2022. ADLARITY is an innovative new treatment option for patients with mild, moderate, or severe dementia of the Alzheimer's type.
    • 16 Mar 2022 According to a KemPharm media release, the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of Corium product ADLARITY by the U.S. Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top